Amyotrophic Lateral Sclerosis - Epidemiology Forecast to 2030

‘Amyotropic Lateral Sclerosis (ALS) - Epidemiology Forecast – 2030’ report delivers an in-depth understanding of the disease, historical and forecasted Amyotropic Lateral Sclerosis (ALS) epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Geographies Covered
• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan
Study Period: 2017–2030

Amyotropic Lateral Sclerosis (ALS) Understanding
Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease, is a group of rare neurological diseases that mainly involve the nerve cells (neurons) responsible for controlling voluntary muscle movement. The disease is progressive, meaning the symptoms get worse over time. In ALS, both the upper motor neurons and the lower motor neurons degenerate or die and stop sending messages to the muscles. Unable to function, the muscles gradually weaken, start to twitch (called fasciculations), and waste away (atrophy). Eventually, the brain loses its ability to initiate and control voluntary movements. The cause of ALS is not known, and it is not yet known why ALS strikes some people and not others. However, evidence from scientific studies suggests that both genetics and environment play a role in the development of ALS.
In ALS, both the upper motor neurons and the lower motor neurons degenerate or die and stop sending messages to the muscles. Unable to function, the muscles gradually weaken, start to twitch (called fasciculations), and waste away (atrophy). Eventually, the brain loses its ability to initiate and control voluntary movements. The cause of ALS is not known, and it is not yet known why ALS strikes some people and not others. However, evidence from scientific studies suggests that both genetics and environment play a role in the development of ALS.
ALS can affect any of the body’s muscles, which is why it affects each person differently. In addition, ALS progresses at different rates in different people. For some, it advances quickly, and in others, the disease shows a much slower pace. Common symptoms include painless, progressive muscle weakness. The first thing a person might notice is tripping more often, or dropping things because of the weakness. Slurred speech, difficulty swallowing, and trouble breathing can occur.
ALS can be either sporadic or genetic. The sporadic type is the most common. It accounts for 90–95% of all cases of ALS. The sporadic type can affect anyone. The genetic or familial type is rarer and accounts for 5–10% of cases of ALS. The terms familial and genetic mean that this type of ALS is inherited. In families who have genetic ALS, there is an up to 50% chance that each child will inherit the gene and develop the disease.

Amyotropic Lateral Sclerosis (ALS) Epidemiology Perspective
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Prevalent Population of Amyotropic Lateral Sclerosis (ALS), Diagnosed Prevalent Population of Amyotropic Lateral Sclerosis (ALS), Gender-specific Distribution of Amyotropic Lateral Sclerosis (ALS), Type-specific Distribution of Amyotropic Lateral Sclerosis (ALS), Mutation-specific Distribution of Amyotropic Lateral Sclerosis (ALS), Site of Onset of Amyotropic Lateral Sclerosis (ALS) and Age-specific Distribution of Amyotropic Lateral Sclerosis (ALS) in the 7MM market covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom) and Japan from 2017 to 2030.

Amyotropic Lateral Sclerosis (ALS) Detailed Epidemiology Segmentation
• The prevalent population of ALS in the seven major markets was found to be 70,456 in 2017.
• The diagnosed prevalent cases of ALS, in the United States, were found to be 45,796 in 2017 and 48,112 in 2020.
• In the United States, the sporadic and familial ALS cases were 16,015 and 1,779, respectively, in 2017.
• In the United States, the number of males and females with ALS were 11,482 and 7,341, respectively, in 2020.
• ALS can be divided into C9ORF72, SOD1, others mutations (TARDBP, FUS, OPTN, ANG, etc.), and non-mutated/unidentified mutation based on the types of mutations causing the condition. In the United States, the number of cases of C9ORF72, SOD1, others mutations (TARDBP, FUS, OPTN, ANG, etc.), and non-mutated/unidentified mutation was 5,783, 2,847, 1,424 and 7,741, respectively, in 2017.
• In the United States, the most diagnosed site of onset of ALS was limb with 8,897 cases, followed by bulbar and cervical with 4,449 and 2,491 cases, and other uncertain regions accounted for 1,957 cases in 2017.
• Age-specific data of ALS suggests that it is more prevalent among the 60–69 age group. In the United States, the maximum number of cases of ALS was observed in the age group of 60–69 with 5,623 cases in 2017, while the lowest number of cases were found in the age group <20, with 94 cases in 2017.However, in Japan 70+ age group pool had more diagnosed prevalent cases as there is higher geriatric population in the country.
• In the EU5 countries, the diagnosed prevalence of ALS was found to be maximum in Germany with 4,806 cases, followed by the France with 3,923 cases in 2017. While, the least number of cases were found in Spain, with 2,735 cases in 2017.
• In Japan, the diagnosed prevalence of ALS was found to be 9,580 in 2020.

Scope of the Report
• The report covers the descriptive overview of Amyotropic Lateral Sclerosis (ALS), explaining its causes, signs and symptoms, pathophysiology.
• The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom) and Japan.
• The report assesses the disease risk and burden and highlights the unmet needs of Amyotropic Lateral Sclerosis (ALS).
• The report provides the segmentation of the disease epidemiology for the 7MM by Prevalent Population of Amyotropic Lateral Sclerosis (ALS), Diagnosed Prevalent Population of Amyotropic Lateral Sclerosis (ALS), Gender-specific Distribution of Amyotropic Lateral Sclerosis (ALS), Type-specific Distribution of Amyotropic Lateral Sclerosis (ALS), Mutation-specific Distribution of Amyotropic Lateral Sclerosis (ALS), Site of Onset of Amyotropic Lateral Sclerosis (ALS) and Age-specific Distribution of Amyotropic Lateral Sclerosis (ALS)

Report Highlights
• Eleven Year Forecast of Amyotropic Lateral Sclerosis (ALS)
• 7MM Coverage
• The analyst examined gender-specific data of ALS, which suggests that ALS is more prevalent in males than in females.
• The analyst has also analysed mutation-specific data of ALS, mutation-specific data of ALS, which suggests that mutations in the C9ORF72 and SOD1 genes are the most common causes of ALS while mutation in several other genes (TARDBP, FUS, OPTN, ANG,etc.) and non-mutated/unidentified mutations are also involved in the development of ALS.
• Type-specific data of ALS suggests that ALS can be divided into two sub-types, namely, Sporadic and Familial ALS.
• Age-specific data of ALS suggests that prevalence of ALS increase with age, especially after the age of 60–69 years.

Key Questions Answered
• What is the disease risk, burden and unmet needs of Amyotropic Lateral Sclerosis (ALS)?
• What is the historical Amyotropic Lateral Sclerosis (ALS) patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK) and Japan?
• What would be the forecasted patient pool of Amyotropic Lateral Sclerosis (ALS) at the 7MM level?
• What will be the growth opportunities across the 7MM with respect to the patient population pertaining to Amyotropic Lateral Sclerosis (ALS)?
• Out of the above-mentioned countries, which country would have the highest prevalent population of Amyotropic Lateral Sclerosis (ALS) during the forecast period (2020–2030)?
• At what CAGR the population is expected to grow across the 7MM during the forecast period (2020–2030)?

Reasons to buy
The Amyotropic Lateral Sclerosis (ALS) report will allow the user to -
• Develop business strategies by understanding the trends shaping and driving the 7MM Amyotropic Lateral Sclerosis (ALS) market.
• Quantify patient share distribution in the 7MM for Amyotropic Lateral Sclerosis (ALS).
• The Amyotropic Lateral Sclerosis (ALS) epidemiology report and model were written and developed by Masters and Ph.D. level epidemiologists.
• The Amyotropic Lateral Sclerosis (ALS) epidemiology model developed is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over the eleven-year forecast period using reputable sources.

Key Assessments
• Patient Segmentation
• Disease Risk and Burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population